iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS
IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY
 
 
  ACTHIV - American Conference for the Treatment of HIV Aug 20-22 2020 virtual Reported by Jules Levin
 
Edgar T. Overton,1 Gary Richmond,2 Giuliano Rizzardini,3 Hans Jaeger,4 Catherine Orrell,5 Firaya Nagimova,6 Fritz Bredeek,7 Miguel GarcĂ­a del Toro,8 Paul D. Benn,9 Yuanyuan Wang,10 Krischan J. Hudson,11 David A. Margolis,11 Kimberly Smith,11 Peter E. Williams,12 William Spreen,11 Paula Teichner11
1University of Alabama at Birmingham, Birmingham, AL, USA; 2Broward General Health Medical Center, Fort Lauderdale, FL, USA; 3Fatebenefratelli Sacco Hospital, Milan, Italy; 4HIV Research and Clinical Care Center, Munich, Germany; 5Desmond Tutu HIV Foundation, University of Cape Town Medical School, Cape Town, South Africa; 6Republic Center for the Prevention and Control of AIDS and Infectious Diseases, Russia; 7Metropolis Medical, San Francisco, CA, USA; 8General Hospital of Valencia, Valencia, Spain; 9ViiV Healthcare, Brentford, UK; 10GlaxoSmithKline, Collegeville, PA, USA; 11ViiV Healthcare, Research Triangle Park, NC, USA; 12Janssen Research & Development, Beerse, Belgium

0825201

0825202

0825203

0825204

0825205

0825206

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org